A Multicenter, Open-Label, Phase 2 Study to Determine the Dose, Safety and Efficacy of NKTR 102 in Combination With Cetuximab Versus Irinotecan in Combination With Cetuximab in Second Line, Irinotecan and Cetuximab Naïve Colorectal Cancer Patients With Metastatic or Locally Advanced Disease
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Establish the recommended Phase 2a dose (RPTD) of the combination of NKTR-102 and cetuximab
12 months
No
Daniel Maslyar, M.D.
Study Director
Nektar Therapeutics
United States: Food and Drug Administration
07-PIR-02
NCT00598975
January 2008
Name | Location |
---|---|
Tyler Cancer Center | Tyler, Texas 75702 |
Louisville Oncology Clinical Research Program | Louisville, Kentucky 40202 |
TGen Clinical Research Services @ Scottsdale Healthcare, Debi & Jerry Bisgrove Research Pavilion | Scottsdale, Arizona 85258 |
Texas Oncology - Baylor Sammons Cancer Center | Dallas, Texas 75426 |